Abstract. The transplantation of organs, cells, and tissues has burgeoned during the last quarter century, with the development of multiple new specialty fields. However, the basic principles that made this possible were established over a three-decade period, beginning during World War II and ending in 1974. At the historical consensus conference held at UCLA in March 1999, 11 early workers in the basic science or clinical practice of transplantation (or both) reached agreement on the most significant contributions of this era that ultimately made transplantation the robust clinical discipline it is today. These discoveries and achievements are summarized here in six tables and annotated with references.
tions about their own unique contributions. The ultimate objective, however, was to reach a consensus by the group on what were the most critical historical discoveries that made transplantation a form of clinical therapy. Carl G. Groth (Stockholm) was invited to be the Chairman for these consensus deliberations and to prepare the executive summary.
Historical landmark status was restricted to contributions made at least a quarter of a century ago. By this time it had been established that rejection of organ allografts could be prevented or reversed with immunosuppressive drugs and that variable donor-specific immunologic tolerance of the graft subsequently developed in many patients. Long-term survival of human recipients of organ and bone marrow allografts had been repeatedly obtained, ensuring continuation of such clinical efforts. A large number of HLA antigens had been discovered, allowing efforts at tissue matching to proceed. The scientific articles annotating this progress are listed in six tables under the following headings: transplantation immunology, bone marrow transplantation, renal transplantation, liver transplantation, heart transplantation, and tissue matching. The material presented in these tables, including the citations, originated from the participants of the symposium.
It should be noted that transplantation could not have proceeded without contemporaneous advances in general and thoracic surgery, medicine, and anesthesia, such as open-heart surgery, renal dialysis, antibiotics, and intensive care technology. The cardiopulmonary resuscitation procedures introduced during the 1950s were particularly influential because they mandated redefinition of death in terms of irreversible brain damage rather than the cessation of heartbeat and respiration. While salvaging countless victims of cardiac or pulmonary arrest, the new methods also resulted in brain-dead corpses on physiologic life support.
In 1966, at a symposium on medical ethics in London, G.P.J. Alexandre described the criteria of brain death that had been used in Belgium and France for discontinuing mechanical ventilation of "heart-beating cadavers." It became possible thereby to remove kidneys and other organs from cadaver donors with an intact circulation. The concept was further elaborated in a Harvardbased ad hoc committee report in 1968 in the Journal of the American Medical Association. The impact on transplantation of cadaver organs was immediate and lasting.
Transplantation Immunology
The modern age of transplantation immunology (Table 1) [1] [2] [3] [4] [5] [6] [7] [8] began with three seminal observations. First, rejection is a hostversus-graft (HVG) immune reaction. Second, a similar immune reaction [graft-versus-host (GVH)] may occur in reverse and lead to lethal graft-versus-host disease (GVHD). Third, it is possible under well defined experimental conditions to avert rejection as well as GVHD and to induce tolerance of alloantigens, which is strongly associated with the persistence in the recipient of donor leukocyte chimerism.
The next step was the recognition that organ allografts are inherently tolerogenic, a property without which their transplantation with long survival in the recipient would not be possible (Table 1 ). The tolerance induced by organs usually is manifested only under an umbrella of immunosuppression, but it is not a prerequisite in some animal models, particularly if the allograft is the leukocyte-rich liver (see also Table 4 ).
The discoveries listed in Table 1 were made piecemeal over a period of 25 years, obscuring the fact that all three of the fundamental phenomena studied by early workers (i.e., HVG, GVH, and acquired tolerance) were involved, but to different degrees, in the "acceptance" of organ allografts and the tolerance induced by allogeneic bone marrow following recipient cytoablation. In 1992 the mechanistic linkage of engraftment after these two kinds of transplantation was established with the discovery of donor leukocyte microchimerism in long-surviving human organ recipients.
The clonal selection theory proposed in 1949 by Burnet and Fenner marked the beginning of a new wave in immunology, from which transplantation is often viewed as a mere stream. Instead, transplantation is a mighty tributary. It fostered research into the mechanisms of the destructive antigraft immune response and the control of this response. From these efforts, directly or indirectly, came the discovery of the function of the lymphocyte (1959 -1961) and the role of the thymus in the ontogeny of the immune system (1961); delineation (1958 -1963) of the human major histocompatibility complex (MHC); distinction of the T and B lymphocyte subsets (1967) (1968) ; and mainly by study of antiviral immune responses, demonstration of the MHC-restricted nature of the adaptive immune response (1968 -1974) .
Bone Marrow Transplantation
Bone marrow transplantation (Table 2) [9 -22] had its roots in radiobiology and hematology, and it was influenced by clinical studies of certain inherited immune deficiency diseases. Early in these efforts it was learned that engraftment of histoincompatible bone marrow can cause lethal GVHD in a recipient rendered immunologically defenseless by cytoablation, a complication also predicted in recipients with immune deficiency disease. Consequently, the preclinical and clinical development of bone marrow transplantation was delayed until reliable methods of HLA typing and matching became available.
The first completely successful bone marrow transplantations were in children with immune deficiency diseases whose family donors were selected with relatively primitive first-generation tissue-matching techniques. Because of their T cell deficiency, these recipients did not require the cytoablation and postgrafting immunosuppression needed with other indications for bone marrow transplantation. With the use of methotrexate as an immunosuppressant in cytoablated recipients, bone marrow transplantation subsequently was applied with steadily improving results in those with an array of benign and malignant hematolymphopoietic dis- eases, other kinds of malignancies, and numerous inborn errors of metabolism.
Kidney Transplantation
Three factors made the kidney a pathfinder organ in transplantation (Table 3 ) [8, . One was the development of dialysis for the treatment of acute, and ultimately chronic, renal failure. The second was the fact that the kidney is a paired organ, ensuring a supply of surgically removed "free kidneys" and, increasingly after 1953, physiologically ideal live donor kidneys. Third, its technical simplicity and the ease with which allograft function could be monitored made kidney transplantation ideal for laboratory and clinical investigation.
By 1974 kidney transplantation had already gone through the four eras shown in Table 3 defined by: no immunosuppression, immunosuppression with total body irradiation (TBI), the first use of drugs to prevent rejection (azathioprine) or reverse it (prednisone), and the introduction of adjunct anti-lymphocyte antibody therapy. Each major improvement in immunosuppression up to 1974 and subsequently permitted goals in kidney transplantation to be reached that were not attainable before.
Thus the transition from no therapy to TBI corresponded with the step from identical to fraternal twin transplantation. The change to azathioprine-based treatment established kidney transplantation as a clinical service from 1963 onward, especially using kidneys from living related donors. Cadaver kidney transplantation burgeoned with the acceptance of brain death during the late 
Liver Transplantation
After a failed trial in 1963, liver transplantation was successfully performed in humans in July 1967 (Table 4 ) [48 -60] . Hepatic replacement was initially viewed as too difficult to be technically feasible, particularly in terminally ill patients for whom artificial organ support comparable to renal dialysis was not available. Instead, challenges generated by its surgical difficulty and physiologic complexity made liver transplantation the co-leader after 1963 (with the kidney) or the leader in the development of broadly applicable advances of surgical technique, immunosuppression, and means of multiple organ procurement and preservation. Despite a high mortality rate during the first year after liver transplantation, nearly two dozen recipients from this early era have been stable for 20 to more than 29 years using immunosuppression with azathioprine, prednisone, and antilymphocyte globulin (ALG). The proof of the liver's unusual tolerogenicity (Tables 1, 4) is that most of these patients have been able to discontinue immunosuppressive therapy without rejecting their grafts.
The ripple effects of liver transplantation included discovery of the first hepatotrophic factors (beginning with insulin) that are involved in hepatic growth control and regeneration. More than two dozen liver-based inborn errors of metabolism have been corrected by liver transplantation, with clarification of disease mechanisms in some.
Heart Transplantation
The landmarks of heart transplantation are summarized in Table  5 the Stanford program recorded its inaugural human case, which was successful. Graft survival after heart transplantation using triple-drug immunosuppression (azathioprine, prednisone, ALG) was essentially equivalent to that of cadaver kidney transplantation. As with kidney and liver transplantation, many of the pioneer cardiac recipients enjoyed an excellent quality of life, ensuring prompt acceptance and widespread application of all these operations when better immunosuppression became available.
Tissue Matching
The ABO blood groups, the compatibility of which was later found to be a requirement for transfusion and for bone marrow and organ transplantation, were discovered in 1901 [70] . Similarly, it was necessary to develop methods to type human tissue antigens and then to determine which were compatible or incompatible with those of the donor (Table 6 ) [70 -94] . This was made possible with the discovery in transfused patients, and in women who had been pregnant, of leukoagglutinating and lymphocytotoxic antibodies that recognized alloantigens.
The introduction of computer-assisted search systems allowed delineation of families of antibodies that reacted with individual alloantigens and also made feasible the grouping of alloantigens into the two closely associated series that are now called HLA-A and HLA-B. The demonstration of crossover of the A and B antigens established HLA as a closely linked supergene. After 1964 use of the microcytotoxicity test greatly facilitated the standardization of HLA typing and the search for HLA antigens. The method was adapted for donor-recipient crossmatching and subsequently for the detection of pretransplant sensitization to HLA alloantigens.
HLA matching has been a stringent requirement for bone marrow transplantation (Table 2) . For organ transplantation, the lymphocytotoxic crossmatch has been of crucial importance. Although there is clear evidence that the HLA system contains the dominant histocompatibility antigens, it has not been possible to identify which mismatches would result in failure. Nonetheless, HLA-identical sibling kidney allografts provide the highest graft survival rates. These are approached by survival rates of zero HLA-mismatched cadaver kidneys, justifying kidney sharing.
Quarter Century after 1974
The advent of cyclosporine two decades ago was a watershed for both bone marrow [95] and organ [96] transplantation. When the new drug was substituted for azathioprine, allograft survival and the quality of recipient life improved dramatically. In particular, the transplantation of cadaver organs was upgraded from a frequently feasible but unpredictable service to a reliable one. The results of organ transplantation were further enhanced after another decade with the introduction of tacrolimus [97] . Other promising drugs and monoclonal antibody preparations have been introduced more recently or are in various stages of preclinical or clinical evaluation. However, the therapeutic principles have remained essentially the same as were originally developed with azathioprine, prednisone, and ALG. With more potent immunosuppressive agents, the field of transplantation has expanded continuously over the last 25 years. Heart-lung and lung transplantations were extensions of the heart procedure. Although survival of a lung recipient for 10 months had been accomplished as early as 1969 [98] , the first examples of survival exceeding 1 year were not reported for heart-lung transplantation until 1982 [99] and for lung transplantation until 1987 [100] . Efforts at transplantation of abdominal organs expanded from the liver-only to the liver combined with small bowel [101] and to the more complex multiple abdominal visceral grafts [102] ; in the end it resulted in successful engraftment of the small bowel alone [103] . Tacrolimus played a crucial role in making the abdominal procedures involving intestine clinically applicable. Although pancreas transplantation was offered at first only to diabetic patients who also were undergoing kidney transplantation for diabetes-associated end-stage renal disease [104] , pancreas transplantation alone has been performed more recently in nonuremic diabetics [105] . The alternative appealing approach of transplanting the isolated islets of Langerhans only was attempted during the 1970s but did not result in success (defined as insulin independence) until 1990 in a patient with postpancreatectomy diabetes [106] and 1991 in a patient with type I diabetes [107] .
Success with this procedure still is achieved only in occasional cases.
Résumé
La transplantation d'organes, de cellules et de tissus a littéralement explosée dans ce dernier quart de siècle, avec le développement d'une multitude de nouvelle spécialités. Cependant, les principes de base qui ont rendu ceci possible ont été établi sur trois décennies, commençant pendant la deuxième guerre mondiale et terminant en 1974. Pendant la conférence de consensus historique tenu à l'UCLA du 25 au 27 mars, 1999, 11 chercheurs sur la transplantation travaillant en sciences 
Resumen
En los últimos 25 años se ha producido un auténtico renacimiento por lo que a trasplantes de órganos, células y tejidos se refiere, lo que ha propiciado el desarrollo de múltiples áreas nuevas de especialización. Sin embargo, los principios que hicieron posible los trasplantes se establecieron hace más de 3 décadas, ya que las investigaciones al respecto se realizaron en el periodo de tiempo comprendido desde los comienzos de la 2 a Guerra Mundial al final de 1974. En la histórica conferencia de consenso, celebrada en UCLA, del 25 al 27 de marzo de 1999, 11 investigadores pioneros, procedentes tanto de las ciencias básicas como de la clínica y del tratamiento mediante trasplantes, alcanzaron un acuerdo sobre, cuáles fueron los hitos más importantes de este periodo, que permitieron que la técnica de los trasplantes sea hoy una especialidad clínica bien definida y en continua expansión. Estos descubrimientos y realizaciones se resumen en 6 tablas y 93 referencias bibliográficas.
